Xiyuan Anjian Pharmaceutical (Beijing) Co., Ltd. (hereinafter referred to as "Xiyuan Anjian"), a drug R&D company focusing on developing innovative therapeutic drugs in the field of pain management, recently announced the completion of a Series A financing round of over RMB 200 million. This round of investment was led by the Beijing Pharmaceutical and Health Industry Investment Fund, with participation from Jinyi Internet, Yingce Capital, Guanghua Wutong, and Proxima Venture Capital. Existing shareholders Shunxi Fund and Qiming Venture Partners continued to invest. Xingyuan Zhitong served as the financial advisor for this transaction. The funds raised will be primarily used for the upcoming pivotal Phase III clinical trial of BR005, the first domestically developed CGRP-based small molecule drug, and will also support the continued expansion of more innovative R&D pipelines in the field of pain management.
XiYuan AnJian is a clinical-stage biopharmaceutical company focused on developing innovative, highly specific analgesics for severe chronic pain conditions, with a particular emphasis on addressing long-standing unmet clinical needs such as facial pain, neuropathic pain, and musculoskeletal pain. The company's vision is to provide safe, effective, and convenient pain management solutions for the many patients worldwide suffering from chronic pain.
Zheng Li, CEO of JinYi Internet, said，"Xiyuan Anjian Pharmaceutical is a biopharmaceutical company with both innovative R&D capabilities and clinical translation strength, demonstrating remarkable professional depth and development potential in the field of pain management. The company's team possesses leading scientific exploration and systematic development capabilities in the research and development of CGRP-targeted small molecule drugs, continuously achieving breakthroughs through independent innovation, demonstrating the ability and confidence of domestic innovative pharmaceutical companies to achieve technological self-reliance in high-barrier target fields.
We highly recognize the clinical prospects of Xiyuan Anjian's core pipeline project, BR005. As the first independently developed CGRP-based small molecule drug in China, BR005 is expected to be effective in treating migraines and..." Broadly encompassing the treatment of chronic pain, this approach balances safety, efficacy, and patient convenience, filling a clinical gap in this field both domestically and globally.
JinYi Interconnect has long focused on chronic pain management, a niche area with significant unmet needs. We believe that XiYuan AnJian has demonstrated a mature R&D system and international perspective in target mechanism research, candidate molecule optimization, and clinical development strategies. In the future, JinYi Interconnect will work closely with the company to actively support its progress in Phase III clinical trials and commercialization, jointly promoting original Chinese innovative drugs to the international stage and bringing new treatment options to chronic pain patients worldwide.
Dr. Li Guochun, founder and CEO of Xiyuan Anjian, stated, “We are grateful to all our new and existing investors for their deep recognition and strong support of the company. The success of this round of financing is a milestone for us. It will further guarantee the subsequent clinical advancement and commercialization of our core pipeline, ensuring that innovative drugs can quickly reach the market and benefit patients in urgent need. At the same time, ample cash flow will enable us to accelerate the development of more innovative drug pipelines, especially in the areas of new pain mechanisms and targets, to build a deeper and broader product moat. This funding will also help the company accelerate its international expansion and establish in-depth cooperation with international pharmaceutical companies, becoming a global leader in innovative pain drug development.”
Mr. Ren Peng, Chairman and General Manager of Shunxi Management Company, stated，"Pain management is an important component of the Healthy China initiative and basic livelihood security. Its unmet clinical needs not only affect patients' quality of life but also carry significant social implications. The investment and performance of the Xiyuan Anjian management team in innovation and execution, especially their innovative overseas capabilities demonstrated in the face of global competition, are truly impressive. We look forward to the company continuing to innovate and make breakthroughs in the field of pain drug development, contributing to the industrialization of Beijing's pharmaceutical and healthcare sector, while also expanding globally to benefit a wider range of patients worldwide."
Tong Maomeng, Executive Director of Yingce Capital, stated, “There is a significant unmet clinical need in the pain management field, and both the global and Chinese markets are in a phase of rapid growth. Xiyuan Anjian has built a globally leading pain drug R&D platform and a differentiated product portfolio focusing on facial pain, musculoskeletal pain, and neuropathic pain. Its most advanced small-molecule CGRP inhibitor pipeline, BR005, is leading the way and is about to begin a registration clinical trial for migraine indications. We look forward to Xiyuan Anjian’s team, led by Dr. Li Guochun, continuing to deepen its expertise in the pain management field, efficiently advancing the clinical development of its pipeline, and growing into a leading innovative company in the pain management field, serving patients in China and around the world.”
Xiang Wentian, Managing Director of Guanghua Wutong, stated, “Although the Chinese pain management market still lags behind the international market in terms of penetration rate and treatment concepts, we have observed that with continuous breakthroughs in the research and development of innovative pain drugs, more and more doctors and patients are beginning to pay attention to the huge clinical demand and importance of pain management, especially migraine treatment. Xiyuan Anjian's BR005 is currently the most advanced domestically produced small-molecule CGRP inhibitor. The commercialization of BR005 is expected to fill the domestic gap and benefit a large number of patients. Guanghua Wutong is firmly optimistic about the company's strategic layout and execution capabilities in the field of innovative drugs. We look forward to the early launch of the company's products, leading the market with innovation and speed, and bringing positive changes to the industry.”
Sun Xiaolu, Managing Partner of Proxima Centauri Ventures, stated, “We are firmly optimistic about the future development of Xiyuan Anjian. The company has accurately positioned itself in the vast pain market, starting with migraines and proactively expanding into chronic pain such as neuropathic pain. In the four years since its establishment, Xiyuan Anjian has built a full-chain R&D capability from project initiation and product selection to product development and model transformation, and has assembled a highly efficient and comprehensive team. Its core pipeline, BR005, is the first domestically produced CGRP small molecule to enter Phase II clinical trials, leading the domestic market and possessing enormous potential. We believe that Xiyuan Anjian has the potential to grow into a leading company in the field of innovative pain drugs in China.”
Dr. Kan Chen, Partner and Co-Head of Healthcare Innovation at Qiming Venture Partners, stated, “We remain firmly optimistic about the enormous market potential and breakthrough opportunities in innovative drugs within the pain management field. The company’s recent positive progress not only reaffirms Xiyuan Anjian’s efficient execution capabilities but also further demonstrates its strength in international innovation. Qiming Venture Partners will continue to support the company’s deep cultivation and development in the pain management field and remains optimistic about its future prospects. We look forward to the company’s continued deepening of R&D and the continuous delivery of more groundbreaking advancements.”
Mr. Fu Jia, Managing Director of Xingyuan Zhitong, said, “It is a great honor to have accompanied the company through three rounds of financing and witnessed Xiyuan Anjian’s growth into a leader in the field of pain treatment in China. The company’s core pipeline has not only successfully filled the gap in the treatment of acute migraine with domestic drugs, but the team has also won international attention and recognition by forward-lookingly developing multiple differentiated pipelines based on its profound insights into biology. We look forward to the company taking this new round of financing as an opportunity to further promote the upgrading of domestic pain diagnosis and treatment awareness, so that internationally innovative therapies originating from China can benefit more patients in urgent need of treatment.”
>>>>
Regarding the Beijing Medical and Health Industry Investment Fund
The Beijing Medical and Health Industry Investment Fund is one of eight funds approved by the Beijing Municipal Government in the past year. It focuses on investing in key industries such as innovative drugs and innovative medical devices, as well as emerging industries such as cell and gene therapy and digital healthcare, injecting new and strong momentum into the development of new quality productivity in Beijing.
>>>>
About Jinyi Internet Co., Ltd.
JinYi Internet is a professional investment firm focused on the technology and healthcare industries, committed to driving industrial innovation and collaborative development through capital empowerment. With "innovation-driven, value-co-creating" as its core philosophy, the company focuses on cutting-edge fields such as biopharmaceuticals, medical devices, digital healthcare, and smart health services, supporting high-growth companies with core technological competitiveness and global potential.
JinYi Internet possesses strong industry research capabilities and rich post-investment management experience. Its team members have backgrounds in the healthcare industry, investment and financing, and corporate operations, enabling it to provide portfolio companies with full-cycle strategic support and resource integration. Through close cooperation with government funds, industry leaders, and research institutions, JinYi Internet is accelerating the construction of an innovative ecosystem covering the integrated development of "technology, industry, and capital," contributing to the high-quality development of China's life sciences and health industry.
>>>>
Regarding Shunxi Fund under Beijing State-owned Assets Management
Beijing Shunxi Private Equity Management Co., Ltd. (“Shunxi Fund”) is a full-lifecycle investment platform under Beijing State-owned Assets Supervision and Administration Commission (SASAC), focusing on strategic emerging industries. Since its establishment, Shunxi Fund has gradually grown from a venture capital platform under SASAC that focuses on “early-stage, small-scale, technology, and Beijing-based investments” into a full-lifecycle investment platform. Through establishing good cooperative relationships with many universities, research institutes, new R&D institutions, municipal and district-level state-owned funds, market-oriented GPs, leading enterprises in the industrial chain, and government departments, it has continuously built a multi-dimensional collaborative support system and accumulated high-quality project resources and post-investment empowerment capabilities with unique advantages and diversified channels.
>>>>
Regarding Yingce Capital
Founded in 2019, INCE Capital is a venture capital firm focused on investing in early-stage to expansion-stage companies, with a focus on innovation in the fields of artificial intelligence, technology, consumer goods, and biotechnology. The "IN" in its English name stands for Intelligent Innovative Investment, while "CE" comes from the pinyin of the Chinese character "策" (ce), signifying strategy and decision-making. INCE Capital is committed to discovering highly promising innovators and empowering future great companies. INCE Capital manages over $1 billion in funds, with investors including top global university endowments, foundations, government-guided funds, funds of funds, and family offices. It currently has offices in Shanghai, Beijing, and Hong Kong, China.
>>>>
Regarding the sycamore tree
Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd., located in Wenjiang District, Chengdu, primarily engages in the operation of government-backed industrial investment funds and the investment management of market-oriented funds. Adhering to a focused, professional, and dedicated business philosophy, the company strategically positions itself within a "FOF + direct investment" fund ecosystem, empowering industrial development through continuous meticulous work and efficient investment. Currently, the company manages approximately RMB 9 billion in assets and, in partnership with leading enterprises, listed companies, and investment institutions, has established over 20 investment funds with a total scale exceeding RMB 46 billion, covering the entire lifecycle of companies. Healthcare is one of Guanghua Wutong Fund's key investment areas, having already invested in numerous high-growth and groundbreaking innovative pharmaceutical and high-end medical device companies, including Kelun Biotech (HK.06990), Fulian Technology, Tongrui Bio, Darui Bio, Weizhizhuo Bio, Jinjiang Electronics, and Haijieya Medical, thus accumulating rich industry resources.
>>>>
About Proxima Ventures
Proxima Ventures is a leading medical technology investment firm in China, focusing on driving groundbreaking innovations with global commercial value. It has invested in over 70 companies, covering high-end medical devices, biotechnology, and life sciences. With "comprehensive empowerment + strategic integration" as its core strategy, Proxima is building a world-leading innovation ecosystem and continuously setting a benchmark for global value in China's healthcare industry.
>>>>
On the principle of "going far and achieving the same goal"
StartPointAdvisors is dedicated to becoming a leading next-generation healthcare investment bank in China. Founded in 2020 and headquartered in Beijing and Shanghai, the company boasts a team with extensive experience from renowned industry institutions. In its four years of operation, the firm has covered all major sub-sectors and all financing stages within the industry. StartPointAdvisors is also one of the few institutions in China with successful experience in private equity financing, mergers and acquisitions, business development, and equity exits
